The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Veteran investors have plunked down a combined $70.8 million in separate deals to buy big industrial hubs in the East Bay.

Ahead of Storm Goretti, British Gas is warning customers to prepare for frozen pipes, boiler pressure drops and timer resets, which can leave ...

Gateway Center, the three-building complex with 129,000 square feet at the corner of East Speedway and North Kolb Road, ...

ISLAMABAD: The Pakistan Telecommunication Authority (PTA) has commenced the grant of Class Licences for the provision of ...

Pakistan’s financial markets are changing fast, but not always in balanced ways. Technology has made investing ...

The Model Context Protocol (MCP) changes this equation. Think of it as the "USB-C for AI." It's an open standard that allows ...